PUBLIC COMPANY
save$SLDBSolid Biosciences Inc.
$SLDB9.1000-6.57%Charlestown, MA, USupdated 10h ago
community read0 votes
pipeline
4
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(4)
pipeline depth4 products
1Preclinical1Phase 12Phase 2
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)
- phase2Microdystrophin Gene Transfer Study in Adolescents and Children With DMD
- phase1A Study of SGT-212 Gene Therapy in Friedreich's Ataxia
- phase1A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
- phase2A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)
- —Evaluation of Home Based Assessments on Participants With DMD
Insider activity
source: SEC Form 4routine RSU / option mechanics (3)
- Apr 2, 26option exerciseSMITH IAN F · director3,441 sh
- Apr 2, 26option exerciseSMITH IAN F · director3,441 sh
- Mar 9, 26grantPERCEPTIVE ADVISORS LLC · 10% owner8,912,655 sh
🐶 Hiring Signal
next earnings Nov 2, 2026
News
no news has mentioned this company yet
Data sources
last refreshed 18m ago
Found something off?
comments(0)
5-min edit window · permanent after that